Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2019, Article ID 6016931, 7 pages
https://doi.org/10.1155/2019/6016931
Research Article

Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma

1Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin Medical University, Harbin, China
2Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, China

Correspondence should be addressed to Yunfu Cui; moc.liamtoh@777iucfy and Zhidong Wang; moc.361@2y89dzw

Tianyi Fang, Hao Wang, Yunfu Cui, and Zhidong Wang contributed equally to this work.

Received 9 October 2018; Revised 3 November 2018; Accepted 5 November 2018; Published 4 February 2019

Guest Editor: Zhongjie Shi

Copyright © 2019 Tianyi Fang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Rizvi, S. A. Khan, C. L. Hallemeier, R. K. Kelley, and G. J. Gores, “Cholangiocarcinoma - evolving concepts and therapeutic strategies,” Nature Reviews Clinical Oncology, vol. 15, no. 2, pp. 95–111, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. S. P. O’Hara, T. H. Karlsen, and N. F. LaRusso, “Cholangiocytes and the environment in primary sclerosing cholangitis: where is the link?” Gut, vol. 66, no. 11, pp. 1873–1877, 2017. View at Publisher · View at Google Scholar · View at Scopus
  3. J. W. Valle, A. Lamarca, L. Goyal, J. Barriuso, and A. X. Zhu, “New horizons for precision medicine in biliary tract cancers,” Cancer Discovery, vol. 7, no. 9, pp. 943–962, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Bridgewater, P. R. Galle, S. A. Khan et al., “Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma,” Journal of Hepatology, vol. 60, no. 6, pp. 1268–1289, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Bagante, T. Tran, G. Spolverato et al., “Perihilar cholangiocarcinoma: number of nodes examined and optimal lymph node prognostic scheme,” Journal of the American College of Surgeons, vol. 222, no. 5, pp. 750–759.e2, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Bird, M. Elmasry, R. Jones et al., “Role of staging laparoscopy in the stratification of patients with perihilar cholangiocarcinoma,” The British Journal of Surgery, vol. 104, no. 4, pp. 418–425, 2017. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Maeta, T. Ebata, E. Hayashi et al., “Pancreatoduodenectomy with portal vein resection for distal cholangiocarcinoma,” The British Journal of Surgery, vol. 104, no. 11, pp. 1549–1557, 2017. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Chaisaingmongkol, A. Budhu, H. Dang et al., “Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma,” Cancer Cell, vol. 32, no. 1, pp. 57–70.e3, 2017. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Jusakul, I. Cutcutache, C. H. Yong et al., “Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma,” Cancer Discovery, vol. 7, no. 10, pp. 1116–1135, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Alvaro, “The challenge of cholangiocarcinoma diagnosis: the turning point is in extracellular vesicles?” Hepatology, vol. 66, no. 4, pp. 1029–1031, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. H. L. Lewis, A. A. Rahnemai-Azar, M. Dillhoff, C. R. Schmidt, and T. M. Pawlik, “Current management of perihilar cholangiocarcinoma and future perspectives,” Chirurgia, vol. 112, no. 3, pp. 193–207, 2017. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Tsukamoto, Y. I. Yamashita, K. Imai et al., “Predictors of cure of intrahepatic cholangiocarcinoma after hepatic resection,” Anticancer Research, vol. 37, no. 12, pp. 6971–6975, 2017. View at Publisher · View at Google Scholar
  13. K. Wang, H. Zhang, Y. Xia, J. Liu, and F. Shen, “Surgical options for intrahepatic cholangiocarcinoma,” Hepatobiliary Surgery and cholangiocarcinoma, vol. 6, no. 2, pp. 79–90, 2017. View at Publisher · View at Google Scholar
  14. I. Hosokawa, H. Shimizu, H. Yoshidome et al., “Surgical strategy for hilar cholangiocarcinoma of the left-side predominance: current role of left trisectionectomy,” Annals of Surgery, vol. 259, no. 6, pp. 1178–1185, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Takahashi, M. Fukasawa, T. Sato et al., “Biliary drainage strategy of unresectable malignant hilar strictures by computed tomography volumetry,” World Journal of Gastroenterology, vol. 21, no. 16, pp. 4946–4953, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Singh, H. S. Mann, C. L. Thukral, and N. R. Singh, “Diagnostic accuracy of MRCP as compared to ultrasound/CT in patients with obstructive jaundice,” Journal of Clinical and Diagnostic Research, vol. 8, no. 3, pp. 103–107, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. R. C. Dolscheid-Pommerich, S. Manekeller, G. Walgenbach-Brünagel et al., “Clinical performance of CEA, CA19-9, CA15-3, CA125 and AFP in gastrointestinal cancer using LOCI™-based assays,” Anticancer Research, vol. 37, no. 1, pp. 353–360, 2017. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Yamashita, G. Passot, T. A. Aloia et al., “Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer,” The British Journal of Surgery, vol. 104, no. 3, pp. 267–277, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. C. J. Verberne, Z. Zhan, E. R. van den Heuvel et al., “Survival analysis of the CEAwatch multicentre clustered randomized trial,” The British Journal of Surgery, vol. 104, no. 8, pp. 1069–1077, 2017. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Felder, A. Kapur, J. Gonzalez-Bosquet et al., “MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress,” Molecular Cancer, vol. 13, no. 1, p. 129, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. I. Bartella and J. F. Dufour, “Clinical diagnosis and staging of intrahepatic cholangiocarcinoma,” Journal of Gastrointestinal and Liver Diseases, vol. 24, no. 4, pp. 481–489, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. J. R. Bergquist, C. A. Puig, C. R. Shubert et al., “Carbohydrate antigen 19-9 elevation in anatomically resectable, early stage pancreatic cancer is independently associated with decreased overall survival and an indication for neoadjuvant therapy: a National Cancer Database Study,” Journal of the American College of Surgeons, vol. 223, no. 1, pp. 52–65, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Gidwani, K. Huhtinen, H. Kekki et al., “A nanoparticle-lectin immunoassay improves discrimination of serum CA125 from malignant and benign sources,” Clinical Chemistry, vol. 62, no. 10, pp. 1390–1400, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Feng, Y. Tian, G. Xu et al., “Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer,” BMC Cancer, vol. 17, no. 1, p. 737, 2017. View at Publisher · View at Google Scholar · View at Scopus
  25. X.-F. Zhang, E. W. Beal, F. Bagante et al., “Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent,” The British Journal of Surgery, vol. 105, no. 7, pp. 848–856, 2018. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Doussot, C. Lim, C. Gómez-Gavara et al., “Multicentre study of the impact of morbidity on long-term survival following hepatectomy for intrahepatic cholangiocarcinoma,” The British Journal of Surgery, vol. 103, no. 13, pp. 1887–1894, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Yoh, E. Hatano, S. Seo et al., “Long-term survival of recurrent intrahepatic cholangiocarcinoma: the impact and selection of repeat surgery,” World Journal of Surgery, vol. 42, no. 6, pp. 1848–1856, 2018. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Komaya, T. Ebata, K. Shirai et al., “Recurrence after resection with curative intent for distal cholangiocarcinoma,” The British Journal of Surgery, vol. 104, no. 4, pp. 426–433, 2017. View at Publisher · View at Google Scholar · View at Scopus
  29. T. Ebata, T. Mizuno, Y. Yokoyama, T. Igami, G. Sugawara, and M. Nagino, “Surgical resection for Bismuth type IV perihilar cholangiocarcinoma,” The British Journal of Surgery, vol. 105, no. 7, pp. 829–838, 2017. View at Publisher · View at Google Scholar · View at Scopus
  30. C. G. Ethun, A. G. Lopez-Aguiar, T. M. Pawlik et al., “Distal cholangiocarcinoma and pancreas adenocarcinoma: are they really the same disease? A 13-institution study from the US extrahepatic biliary malignancy consortium and the central pancreas consortium,” Journal of the American College of Surgeons, vol. 224, no. 4, pp. 406–413, 2017. View at Publisher · View at Google Scholar · View at Scopus
  31. G. Atanasov, K. Schierle, H. M. Hau et al., “Prognostic significance of tumor necrosis in hilar cholangiocarcinoma,” Annals of Surgical Oncology, vol. 24, no. 2, pp. 518–525, 2017. View at Publisher · View at Google Scholar · View at Scopus
  32. S. G. Farid, A. White, N. Khan, G. J. Toogood, K. R. Prasad, and J. P. A. Lodge, “Clinical outcomes of left hepatic trisectionectomy for hepatobiliary malignancy,” The British Journal of Surgery, vol. 103, no. 3, pp. 249–256, 2016. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Takagi, Y. Yokoyama, T. Kokuryo, J. Yamaguchi, and M. Nagino, “Liver regeneration following experimental major hepatectomy with choledochojejunostomy,” The British Journal of Surgery, vol. 102, no. 11, pp. 1410–1417, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. J. H. Kim, H. K. Yoon, G. Y. Ko et al., “Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization,” Radiology, vol. 255, no. 1, pp. 270–277, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. P. B. Olthof, J. K. Wiggers, B. Groot Koerkamp et al., “Postoperative liver failure risk score: identifying patients with resectable perihilar cholangiocarcinoma who can benefit from portal vein embolization,” Journal of the American College of Surgeons, vol. 225, no. 3, pp. 387–394, 2017. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Li, D. J. Li, J. Chen et al., “Application of joint detection of AFP, CA19-9, CA125 and CEA in identification and diagnosis of cholangiocarcinoma,” Asian Pacific Journal of Cancer Prevention, vol. 16, no. 8, pp. 3451–3455, 2015. View at Publisher · View at Google Scholar · View at Scopus
  37. H. J. Hu, H. Mao, Y. Q. Tan et al., “Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma,” Springerplus, vol. 5, no. 1, p. 551, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Juntermanns, S. Radunz, M. Heuer et al., “Tumor markers as a diagnostic key for hilar cholangiocarcinoma,” European Journal of Medical Research, vol. 15, no. 8, pp. 357–361, 2010. View at Publisher · View at Google Scholar
  39. I. Hatzaras, C. Schmidt, P. Muscarella, W. S. Melvin, E. C. Ellison, and M. Bloomston, “Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies,” HPB: The Official Journal of the International Hepato Pancreato Biliary Association, vol. 12, no. 2, pp. 134–138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. J. M. Banales, V. Cardinale, G. Carpino et al., “Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA),” Nature Reviews. Gastroenterology & Hepatology, vol. 13, no. 5, pp. 261–280, 2016. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Sapisochin, M. Facciuto, L. Rubbia-Brandt et al., “Liver transplantation for “very early” intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment,” Hepatology, vol. 64, no. 4, pp. 1178–1188, 2016. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Tsukahara, T. Ebata, Y. Shimoyama et al., “Residual carcinoma in situ at the ductal stump has a negative survival effect: an analysis of early-stage cholangiocarcinomas,” Annals of Surgery, vol. 266, no. 1, pp. 126–132, 2017. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Y. Bangarulingam, E. Bjornsson, F. Enders et al., “Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis,” Hepatology, vol. 51, no. 1, pp. 174–180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. P. L. Lian, Y. Chang, X. C. Xu, Z. Zhao, X. Q. Wang, and K. S. Xu, “Pancreaticoduodenectomy for duodenal papilla carcinoma: a single-centre 9-year retrospective study of 112 patients with long-term follow-up,” World Journal of Gastroenterology, vol. 23, no. 30, pp. 5579–5588, 2017. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Rizvi and G. J. Gores, “Pathogenesis, diagnosis, and management of cholangiocarcinoma,” Gastroenterology, vol. 145, no. 6, pp. 1215–1229, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. X. W. Huang, Y. Huang, L. D. Chen et al., “Potential diagnostic performance of contrast-enhanced ultrasound and tumor markers in differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma,” Journal of Medical Ultrasonics, vol. 45, no. 2, pp. 231–241, 2018. View at Publisher · View at Google Scholar · View at Scopus
  47. R. A. Carr, M. T. Yip-Schneider, S. Dolejs et al., “Pancreatic cyst fluid vascular endothelial growth factor a and carcinoembryonic antigen: a highly accurate test for the diagnosis of serous cystic neoplasm,” Journal of the American College of Surgeons, vol. 225, no. 1, pp. 93–100, 2017. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Q. He, K. Wang, W. J. Wang, Y. L. Yu, and J. H. Wang, “Smart DNA machine for carcinoembryonic antigen detection by exonuclease III-assisted target recycling and DNA walker cascade amplification,” Analytical Chemistry, vol. 89, no. 17, pp. 9292–9298, 2017. View at Publisher · View at Google Scholar · View at Scopus
  49. B. Le Roy, M. Gelli, G. Pittau et al., “Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma,” The British Journal of Surgery, vol. 105, no. 7, pp. 839–847, 2017. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Shafaghi, F. Mansour- Ghanaei, F. Joukar, F. Nabavi, A. Mansour- Ghanaei, and A. Esrafilian Soltani, “Stage association of preoperative serum carcinoembryonic antigen with gastric adenocarcinoma in Iranian patients,” Asian Pacific Journal of Cancer Prevention, vol. 18, no. 10, pp. 2669–2672, 2017. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Yamada, T. Ebata, Y. Yokoyama et al., “Pulmonary metastasis after resection of cholangiocarcinoma: incidence, resectability, and survival,” World Journal of Surgery, vol. 41, no. 6, pp. 1550–1557, 2017. View at Publisher · View at Google Scholar · View at Scopus